Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line

References

• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–11. doi:https://doi.org/10.1093/glycob/cwv065.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21:949–59. doi:https://doi.org/10.1093/glycob/cwr027.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology. 2009;19:240–49. doi:https://doi.org/10.1093/glycob/cwn120.
   PubMed Web of Science ®Google Scholar
• Keck R, Nayak N, Lerner L, Raju S, Ma S, Schreitmueller T, Chamow S, Moorhouse K, Kotts C, Jones A. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals. 2008;36:49–60. doi:https://doi.org/10.1016/j.biologicals.2007.05.004.
   PubMed Web of Science ®Google Scholar
• Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Evaluating and reporting the immunogenicity impacts for biological products: a clinical pharmacology perspective. AAPS J. 2016;18:395–403. doi:https://doi.org/10.1208/s12248-015-9857-y.
   PubMed Web of Science ®Google Scholar
• Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals. 2008;36:41–47. doi:https://doi.org/10.1016/j.biologicals.2007.05.003.
   PubMed Web of Science ®Google Scholar
• Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs. 2012;4:509–20. doi:https://doi.org/10.4161/mabs.20450.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17:104–18. doi:https://doi.org/10.1093/glycob/cwl057.
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of altered CH2 associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human IgG1. J Exp Med. 1994;180:1087–96. doi:https://doi.org/10.1084/jem.180.3.1087.
   PubMed Web of Science ®Google Scholar
• Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. Differential clearance of glycoforms of IgG in normal and autoimuune-prone mice. Clin Exp Immunol. 1996;106:259–64. doi:https://doi.org/10.1046/j.1365-2249.1996.d01-847.x.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:https://doi.org/10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem. 2006;349:197–207. doi:https://doi.org/10.1016/j.ab.2005.11.012.
   PubMed Web of Science ®Google Scholar
• Lagasse HA, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, Kimchi-Sarfaty C. Recent advances in (therapeutic protein) drug development. F1000Res. 2017;6:113. doi:https://doi.org/10.12688/f1000research.9970.1.
   PubMedGoogle Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs. 2018;10:183–203. doi:https://doi.org/10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104:1866–84. doi:https://doi.org/10.1002/jps.24444.
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28:863–67. doi:https://doi.org/10.1038/nbt.1651.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109–17. doi:https://doi.org/10.1056/NEJMoa074943.
   PubMed Web of Science ®Google Scholar
• Bosques CJ, Collins BE, Meador JW 3rd, Sarvaiya H, Murphy JL, Dellorusso G, Bulik DA, Hsu IH, Washburn N, Sipsey SF, et al. Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat Biotechnol. 2010;28:1153–56. doi:https://doi.org/10.1038/nbt1110-1153.
   PubMed Web of Science ®Google Scholar
• Higel F, Seidl A, Sorgel F, Friess W. N-Glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm. 2016;100:94–100. doi:https://doi.org/10.1016/j.ejpb.2016.01.005.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574–76. doi:https://doi.org/10.1038/nbt.1912.
   PubMed Web of Science ®Google Scholar
• Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135:589–596;quiz 597. doi:https://doi.org/10.1016/j.jaci.2014.12.1947.
   Google Scholar
• Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1298473. doi:https://doi.org/10.1155/2016/1298473.
   PubMed Web of Science ®Google Scholar
• Galili U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation. 2004;78:1093–98. doi:https://doi.org/10.1097/01.TP.0000142673.32394.95.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58. doi:https://doi.org/10.1038/clpt.2008.170.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr. 2013;104:471–79. doi:https://doi.org/10.1016/j.ad.2013.02.005.
   PubMedGoogle Scholar
• Sailstad JM, Amaravadi L, Clements-Egan A, Gorovits B, Myler HA, Pillutla RC, Pursuhothama S, Putman M, Rose MK, Sonehara K, et al. A white paper: consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 2014;16:488–98. doi:https://doi.org/10.1208/s12248-014-9582-y.
   PubMed Web of Science ®Google Scholar
• Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology. 2013;140:1–11. doi:https://doi.org/10.1111/imm.12110.
   PubMed Web of Science ®Google Scholar
• Rispens T, Derksen NI, Commins SP, Platts-Mills TA, Aalberse RC. IgE production to alpha-gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B. PLoS One. 2013;8:e55566. doi:https://doi.org/10.1371/journal.pone.0055566.
   PubMed Web of Science ®Google Scholar
• Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16:658–73. doi:https://doi.org/10.1208/s12248-014-9599-2.
   PubMed Web of Science ®Google Scholar
• Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil FP. Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins. J Immunol Res. 2016;2016:2342187. doi:https://doi.org/10.1155/2016/2342187.
   PubMed Web of Science ®Google Scholar